Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy

Conclusions
Our study reports a novel anti-angiogenesis mechanism of anlotinib via inhibiting CCL2 in an NCI-H1975-derived xenograft model and suggests that changes in serum CCL2 levels may be used to monitor and predict clinical outcomes in anlotinib-administered refractory advanced NSCLC patients using third-line therapy or beyond.

Source: European Respiratory Journal - March 6, 2019 Category: Respiratory Medicine Authors: Lu, J., Zhong, H., Chu, T., Zhang, X., Li, R., Sun, J., Zhong, R., Yang, Y., Alam, M. S., Lou, Y., Xu, J., Zhang, Y., Wu, J., Li, X., Zhao, X., Li, K., Lu, L., Han, B. Tags: Lung cancer Original Articles: Lung cancer Source Type: research